Cardiac stem cell therapy has achieved development in clinical trials
Researchers from United States have gain results in a clinical trial using stem cell therapy to treat myocardial infarction, the lancet, British medical journal reported it online on 14th.
Researchers at the university of louisville and other institutions reported that 16 patients with heart attacks received stem cell therapy. Myocardial infarction refers to a series of symptoms caused by myocardial ischemia because of the damage of cardiovascular function and other reasons. Nowadays, cardiovascular bypass surgery is commonly used to relieve the symptoms, which refers that manually connecting a section of blood vessels to supply blood to the myocardial ischemia site. The stem cells that were used in the study were derived from heart tissue taken during bypass surgery.
Stem cells are cells that have not yet fully developed into adult cells and have the potential to grow into specific organs. The researchers cultured the stem cells in a test tube and injected this large number of them back into their owners' hearts after about four months, hoping they would grow into new healthy heart tissue
In these patients, the chance of the left ventricle pumping blood out of the ventricle normally during a heartbeat was reduced to 30.3.% because of damage to the heart muscle, the results showed. But this rate has risen to 38.5% after being treated with stem cells therapy.
Researcher Roberto Boly said the results were a surprise and could be a major advance in cardiovascular medicine if further research is showing support to the effectiveness of the cardiac stem cell therapy.
- June 18, 2019Recently, researchers from the institute of animal sciences of the Chinese academy of sciences confirmed that dermal stem cells will undergo a cellular senescence phenomenon when the environment chang...view
- December 13, 2018On the ASCB/EMBO meeting in San Diego, CA from Dec 8-12, Countstar exhibited together with his Lafayette based distribution partner Flotek the newest generation of the Countstar cell culture analysers...view
- July 23, 2018The CAR-T Congress gathers thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors. Discussing...view